RWS joins the Electronic Clinical Outcome Assessment (eCOA) Consortium

Chalfont Saint Peter, UK
8/1/2022 9:00:00 AM

RWS, a content solutions company, powered by technology and human expertise, today announces that it has joined Critical Path Institute’s Electronic Clinical Outcome Assessment (eCOA) Consortium to help drive the science, best practice and adoption of eCOA within clinical trials.

The eCOA Consortium was established by the Critical Path Institute (C-Path) in 2011. Its 19 member firms collaborate to support and conduct novel research, design and deliver educational resources and develop and share best-practice recommendations for the electronic collection of clinical outcome data. An eCOA replaces the traditional paper-based approach to collecting patient results, feedback and experiences in clinical trials and studies.

“C-Path is proud and excited to welcome RWS as the newest member of the eCOA Consortium,” said Scottie Kern, Executive Director of the eCOA Consortium, “RWS has a major presence in the eCOA space and is the type of organization that can bring a unique perspective on multilingual eCOA implementation, and, together with other consortium members, will help further drive improvements in this critical step in the clinical trial process.”

RWS’s expertise is built on a long history in linguistically validating over 20,000 clinical outcome assessments into 500+ language pairs in over 200 different specific therapeutic and disease areas, including cardiovascular, allergy, respiratory, oncology, gastroenterology, inflammation, neurology, infectious diseases and vaccines.

“We’re always looking for ways to pioneer and shape the future of our industry,” explains Alisa Heinzman, Manager of eCOA Solutions, RWS. “Joining the Consortium demonstrates our commitment to our clients and the industry by helping to drive the science, best practice and adoption of eCOA within clinical assessments.”

RWS’s state-of-the-art linguistic validation process and eCOA services ensure both the accuracy and timely completion of projects. Global relationships with translators, interviewers, instrument developers, survey research experts, clinicians and in-country reviewers ensure that each linguistic validation project is expedited with ease and scientific accuracy.

About us

RWS is a global AI solutions company empowering the world’s most trusted enterprise AI.

Our proprietary Cultural Intelligence Layer, powered by 250,000 data specialists, cultural and language experts and deep domain professionals, backed by 45+ patents, makes enterprise AI culturally fluent, contextually accurate and secure, ensuring every interaction reflects a brand’s tone, context and customer values.

Through our Generate, Transform and Protect segments, we deliver intelligent content, enterprise knowledge, large-scale localization and IP protection for global growth. Trusted by 80+ of the world’s top 100 brands, RWS provides the confidence, governance and expertise organizations need to deploy AI safely, responsibly and at scale.

Headquartered in the UK, RWS is listed on AIM (RWS.L).

For further information, please visit: rws.com.

© 2025 All rights reserved. Information contained herein is deemed confidential and the proprietary information of RWS Group*.
*RWS Group shall mean RWS Holdings plc for and on behalf of its affiliates and subsidiaries.